PDCD1 and non-small cell lung carcinoma: Similarly, CANOPY-2, a trial investigating the role of canakinumab in patients with NSCLC previously treated with PD-1/PD-L1 inhibitors and platinum-based chemotherapy, did not show significant improvement in PFS or OS in previously treated patients with advanced or metastatic NSCLC who received canakinumab with docetaxel compared to docetaxel alone [90].